A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in patients with Thrombocytopenia and Primary Myelofibrosis
A study for patients with Thrombocytopenia and Primary Myelofibrosis using study drug pacritinib
Sponsor: CTI BioPharma
Enrolling: Male and Female Patients
IRB Number: AAAP1153
U.S. Govt. ID: NCT02055781
Contact: Ryan Shelton: 212-304-5485 / rs3323@columbia.edu
Additional Study Information: This is a clinical research study for subjects with Myelofibrosis (Primary, Post-Polycythemia Vera, and Post-Essential Thrombocytopenia) and thrombocytopenia. The purpose of this study is to determine if pacritinib is better at reducing spleen size and a reduction in symptoms than the best available therapy. This is a randomized, controlled study. Randomized means individuals will be selected by chance to enter one of the three treatment groups - either the experimental drug Pacritinib, available in two different doses, or best available therapy. Individuals will be taking active study medication, either Pacritinib or best available therapy regardless of the treatment group.
This study is closed
Mark Heaney, MD, PhD
Do You Qualify?
Are you 18 years of age or older? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ryan Shelton